Purpose: To explore the tumor proteome of patients diagnosed with localized clear cell renal cancer (ccRCC) and treated with surgery. Material and methods: A total of 165 FFPE tumor samples from patients diagnosed with ccRCC were analyzed using DIA-proteomics. Proteomics ccRCC subtypes were defined using a consensus cluster algorithm (CCA) and characterized by a functional approach using probabilistic graphical models and survival analyses. Results: We identified and quantified 3091 proteins, including 2026 high-confidence proteins. Two proteomics subtypes of ccRCC (CC1 and CC2) were identified by CC using the high-confidence proteins only. Characterization of molecular differences between CC1 and CC2 was performed in two steps. First, we d...
PURPOSE: Tumor stage and nuclear grade are the most important prognostic parameters of clear cell re...
<b>Background:</b> Proteomics-based approaches for biomarker discovery are promising st...
Purpose: To enhance prognostic information of protein biomarkers for clear cell renal cell carcinoma...
Purpose: To explore the tumor proteome of patients diagnosed with localized clear cell renal cancer ...
*S Supporting Information ABSTRACT: Clear cell renal cell carcinoma is the most prevalent of all rep...
Purpose We attempted to detect, for the first time in a Brazilian cohort, differences in protein...
Renal cell carcinoma comprises 2 to 3% of malignancies in adults with the most prevalent subtype bei...
Clear cell renal cell carcinoma (ccRCC) is the third most common and most malignant urological cance...
Clear cell renal cell carcinoma is the most prevalent of all reported kidney cancer cases, and curre...
OBJECTIVE: To investigate discriminating protein patterns and serum biomarkers between clear cell re...
Objective: To investigate discriminating protein patterns and serum biomarkers between clear cell re...
To elucidate the deregulated functional modules that drive clear cell renal cell carcinoma (ccRCC), ...
Renal clear cell carcinoma (ccRCC) comprises over 75% of all renal tumors and arises in the epitheli...
The promise of personalized medicine is a therapeutic advance where tumor signatures obtained from d...
Clear cell renal cell carcinoma is the most prevalent of all reported kidney cancer cases, and curre...
PURPOSE: Tumor stage and nuclear grade are the most important prognostic parameters of clear cell re...
<b>Background:</b> Proteomics-based approaches for biomarker discovery are promising st...
Purpose: To enhance prognostic information of protein biomarkers for clear cell renal cell carcinoma...
Purpose: To explore the tumor proteome of patients diagnosed with localized clear cell renal cancer ...
*S Supporting Information ABSTRACT: Clear cell renal cell carcinoma is the most prevalent of all rep...
Purpose We attempted to detect, for the first time in a Brazilian cohort, differences in protein...
Renal cell carcinoma comprises 2 to 3% of malignancies in adults with the most prevalent subtype bei...
Clear cell renal cell carcinoma (ccRCC) is the third most common and most malignant urological cance...
Clear cell renal cell carcinoma is the most prevalent of all reported kidney cancer cases, and curre...
OBJECTIVE: To investigate discriminating protein patterns and serum biomarkers between clear cell re...
Objective: To investigate discriminating protein patterns and serum biomarkers between clear cell re...
To elucidate the deregulated functional modules that drive clear cell renal cell carcinoma (ccRCC), ...
Renal clear cell carcinoma (ccRCC) comprises over 75% of all renal tumors and arises in the epitheli...
The promise of personalized medicine is a therapeutic advance where tumor signatures obtained from d...
Clear cell renal cell carcinoma is the most prevalent of all reported kidney cancer cases, and curre...
PURPOSE: Tumor stage and nuclear grade are the most important prognostic parameters of clear cell re...
<b>Background:</b> Proteomics-based approaches for biomarker discovery are promising st...
Purpose: To enhance prognostic information of protein biomarkers for clear cell renal cell carcinoma...